AUTHORS
Yun Zhang II, MMed, Bo Wang2, Dijiong Wu, MD,PhD3, Shu Deng, MD4, Jianping Shen5, Yanting Gao6, Wenbin Liu, MD,PhD7, Qinghong Yu Jr, Practicing Certificate for Licensed Physician8, Tonglin Hu9, Yingying Shen10, Xiawan Yang11, Wenbin Qian, MD12, Dan Chen13, Weiying Feng14, Baodong Ye, MD, PhD15
AFFILIATIONS
1 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), hangzhou, Zhejiang, China
2 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), hangzhou, Zhejiang, China
3 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), hangzhou, Zhejiang, China
4 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), hangzhou, Zhejiang, China
5 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), hangzhou, Zhejiang, China
6 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), hangzhou, Zhejiang, China
7 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), hangzhou, Zhejiang, China
8 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), hangzhou, Zhejiang, China
9 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), hangzhou, Zhejiang, China
10 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), hangzhou, Zhejiang, China
11 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), hangzhou, Zhejiang, China
12 The Second Affiliated Hospital Zhejiang University School of Medicine, hangzhou, Zhejiang, China
13 the fourth affiliated hospital, Zhejang university school of medicine, Yiwu, Zhejiang, China
14 Shaoxing People's Hospital, Shaoxing, Zhejiang, China
15 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), hangzhou, Zhejiang, China
ABSTRACT
Introduction
Aplastic anemia (AA) is a bone marrow failure syndrome characterized by peripheral pancytopenia and hypocellular bone marrow. Although thrombopoietin receptor agonists (TPO-RAs) have improved outcomes in severe AA (SAA), prospective evidence in patients with non-severe AA (NSAA) and severe thrombocytopenia remains limited. Romiplostim N01, the first domestically developed romiplostim biosimilar approved in China, has not been prospectively evaluated in this population. We evaluated the efficacy, safety, clonal evolution, and exploratory biomarker analyses of a fixed initial-dose romiplostim N01 plus cyclosporine (CsA) regimen in NSAA patients with severe thrombocytopenia.
Methods
In this prospective, open-label, multicenter, single-arm phase II study (ChiCTR2500096280), 41 patients with NSAA and severe thrombocytopenia (platelet count<30×10?/L) were enrolled between August 2024 and January 2026. Patients received Romiplostim N01 at a fixed initial dose of 10 μg/kg weekly plus CsA for 24 weeks, with dose tapering to 5 μg/kg when platelet counts exceeded 100×10?/L and discontinuation when counts exceeded 200×10?/L. The primary endpoint was overall response rate (ORR) at weeks 12 and 24. Secondary endpoints included hematologic responses at weeks 4 and 25, safety, cytogenetic changes, and clonal evolution. Exploratory analyses evaluated associations of telomere length, telomerase reverse transcriptase (TERT)/telomerase RNA component (TERC) alterations, TERT expression, putative germline variants identified by baseline whole-exome sequencing (WES), and longitudinal clonal dynamics assessed by targeted next-generation sequencing (NGS) with hematologic response.
Results
Forty-one patients (median age, 44 years [range, 15-76]; 21 [51.2%] male) were included in the intention-to-treat analysis. Median baseline hemoglobin and platelet counts were 79.0 (IQR, 65.0–109.0) g/L and 16.0 (IQR, 10.0-21.5) ×10?/L, respectively. The median time to platelet response was 5.0 weeks (95% CI, 4.1-5.9). At week 4, platelet, hemoglobin, and neutrophil response rates were 46.3% (19/41), 38.7% (12/31), and 33.3% (13/39), respectively. The primary endpoint was achieved, with ORRs of 73.2% (30/41) at week 12 and 70.7% (29/41) at week 24. The complete remission (CR) rate increased from 7.3% (3/41) to 19.5% (8/41), and 90.0% (27/30) of week-12 responders maintained their response through week 24.
Among the 23 patients who completed 6 months of post-treatment follow-up, 17 (73.9%) maintained at least a partial remission (PR), including 16 who sustained their week-24 response and 1 who achieved a delayed response after treatment completion. Treatment was well tolerated. Grade 1 myelofibrosis occurred in one patient and transient liver enzyme elevations in three. No grade ≥3 treatment-related adverse events, treatment-related deaths, thromboembolic events, or progression to MDS/AML were observed.
Baseline WES data were available for 27 patients to identify putative germline variants. Sixteen (59.3%) carried putative germline variants, most commonly in RTEL1 and SLX4 (3 patients each), and baseline putative germline variant status was not associated with week-24 hematologic response (68.8% vs. 72.7%; P=1.000). Longitudinal clonal dynamics were evaluated using paired targeted NGS of baseline and end-of-treatment samples from 32 patients. Clonal stability was observed in 16 (50.0%), new clones in 7 (21.9%), clone loss in 7 (21.9%), and clonal replacement in 2 (6.3%), with no association between clonal evolution and treatment response (P=0.405). Exploratory biomarker analyses showed numerically lower CR rates in patients with short telomeres and numerically higher CR rates in those with TERT/TERC alterations or detectable TERT expression, though none reached statistical significance (all P>0.05).
Conclusions
Romiplostim N01 at a fixed initial dose of 10 µg/kg weekly plus cyclosporine induced rapid, durable, and well-tolerated hematologic responses in NSAA patients with severe thrombocytopenia. Sustained overall responses, increasing CR rates over time, favorable safety, and maintenance of hematologic responses after treatment completion support further prospective evaluation of this regimen. No association was observed between treatment response and baseline putative germline variant status or clonal dynamics. Larger prospective studies with longer follow-up are warranted to validate these findings.
DISCLOSURES
Yun Zhang II, MMed: No relevant conflicts of interest to declare.